全文获取类型
收费全文 | 179658篇 |
免费 | 11477篇 |
国内免费 | 906篇 |
专业分类
耳鼻咽喉 | 1896篇 |
儿科学 | 5751篇 |
妇产科学 | 4309篇 |
基础医学 | 25204篇 |
口腔科学 | 6820篇 |
临床医学 | 16277篇 |
内科学 | 39576篇 |
皮肤病学 | 4476篇 |
神经病学 | 18462篇 |
特种医学 | 4310篇 |
外国民族医学 | 2篇 |
外科学 | 17697篇 |
综合类 | 975篇 |
一般理论 | 114篇 |
预防医学 | 18153篇 |
眼科学 | 3086篇 |
药学 | 12459篇 |
中国医学 | 671篇 |
肿瘤学 | 11803篇 |
出版年
2023年 | 1729篇 |
2022年 | 1427篇 |
2021年 | 5848篇 |
2020年 | 4091篇 |
2019年 | 5678篇 |
2018年 | 6676篇 |
2017年 | 4731篇 |
2016年 | 5326篇 |
2015年 | 5921篇 |
2014年 | 7648篇 |
2013年 | 9951篇 |
2012年 | 15334篇 |
2011年 | 15821篇 |
2010年 | 8476篇 |
2009年 | 7133篇 |
2008年 | 12194篇 |
2007年 | 12048篇 |
2006年 | 11136篇 |
2005年 | 10305篇 |
2004年 | 9343篇 |
2003年 | 8204篇 |
2002年 | 7374篇 |
2001年 | 1619篇 |
2000年 | 1416篇 |
1999年 | 1408篇 |
1998年 | 1054篇 |
1997年 | 831篇 |
1996年 | 691篇 |
1995年 | 723篇 |
1994年 | 667篇 |
1993年 | 550篇 |
1992年 | 651篇 |
1991年 | 559篇 |
1990年 | 523篇 |
1989年 | 465篇 |
1988年 | 458篇 |
1987年 | 377篇 |
1986年 | 344篇 |
1985年 | 308篇 |
1984年 | 290篇 |
1983年 | 281篇 |
1982年 | 232篇 |
1981年 | 205篇 |
1980年 | 207篇 |
1979年 | 197篇 |
1978年 | 161篇 |
1977年 | 136篇 |
1976年 | 110篇 |
1975年 | 117篇 |
1974年 | 113篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Buket Bakan Fatih Oltulu Yeliz Y?ld?r?m Altu? Yava?o?lu Sinan Akg?l Nefise ülkü Karabay Yava?o?lu 《Arhiv za higijenu rada i toksikologiju》2023,74(3):207
The aim of this safety study in mice was to determine in vivo toxicity and biodistribution potential of a single and multiple doses of L-glutamic acid-g-p(HEMA) polymeric nanoparticles as a drug delivery system. The single dose did not cause any lethal effect, and its acute oral LD50 was >2.000 mg/kg body weight (bw). Multiple doses (25, 50, or 100 mg/kg bw) given over 28 days resulted in no significant differences in body and relative organ weights compared to control. These results are supported by biochemical and histological findings. Moreover, nanoparticle exposure did not result in statistically significant differences in micronucleus counts in bone marrow cells compared to control. Nanoparticle distribution was time-dependent, and they reached the organs and even bone marrow by hour 6, as established by ex vivo imaging with the IVIS® spectrum imaging system. In conclusion, L-glutamic acid-g-p(HEMA) polymeric nanoparticles appear biocompatible and have a potential use as a drug delivery system.KEY WORDS: biocompatibility, blood biochemistry, genotoxicity, histology, in vivo toxicity, micronucleus test, polymers 相似文献
2.
Malou A.H. Nuijten Thijs M.H. Eijsvogels Valerie M. Monpellier Ignace M.C. Janssen Eric J. Hazebroek Maria T.E. Hopman 《Obesity reviews》2022,23(1):e13370
Postbariatric loss of muscle tissue could negatively affect long-term health due to its role in various bodily processes, such as metabolism and functional capacity. This meta-analysis aimed to unravel time-dependent changes in the magnitude and progress of lean body mass (LBM), fat-free mass (FFM), and skeletal muscle mass (SMM) loss following bariatric surgery. A systematic literature search was conducted in Pubmed, Embase, and Web of Science. Fifty-nine studies assessed LBM (n = 37), FFM (n = 20), or SMM (n = 3) preoperatively and ≥1 time points postsurgery. Random-effects meta-analyses were performed to determine pooled loss per outcome parameter and follow-up time point. At 12-month postsurgery, pooled LBM loss was ?8.13 kg [95%CI ?9.01; ?7.26]. FFM loss and SMM loss were ?8.23 kg [95%CI ?10.74; ?5.73] and ?3.18 kg [95%CI ?5.64; ?0.71], respectively. About 55% of 12-month LBM loss occurred within 3-month postsurgery, followed by a more gradual decrease up to 12 months. Similar patterns were seen for FFM and SMM. In conclusion, >8 kg of LBM and FFM loss was observed within 1-year postsurgery. LBM, FFM, and SMM were predominantly lost within 3-month postsurgery, highlighting that interventions to mitigate such losses should be implemented perioperatively. 相似文献
3.
4.
Rizzo Giuseppe Pietrolucci Maria Elena Capponi Alessandra Mappa Ilenia 《The international journal of cardiovascular imaging》2022,38(5):1017-1019
The International Journal of Cardiovascular Imaging - 相似文献
5.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献
6.
Olivari Davide De Giorgio Daria Staszewsky Lidia Irene Fumagalli Francesca Boccardo Antonio Novelli Deborah Manfredi Martina Babini Giovanni Luciani Anita Ruggeri Laura Magliocca Aurora Zani Davide Danilo Masson Serge Belloli Angelo Pravettoni Davide Maiocchi Giuseppe Latini Roberto Ristagno Giuseppe 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》2022,36(4):727-738
Cardiovascular Drugs and Therapy - Available animal models of acute heart failure (AHF) and their limitations are discussed herein. A novel and preclinically relevant porcine model of decompensated... 相似文献
7.
Bradshaw Paige Garber Keegan Shaun Foertsch Madeline Yang George L. Ngwenya Laura B. Srinivasan Vasisht 《Journal of thrombosis and thrombolysis》2022,54(2):295-300
Journal of Thrombosis and Thrombolysis - The ongoing controversy regarding optimal reversal agent for factor Xa-inhibitors is mainly due to lack of comparative data of andexanet alfa (AA) to... 相似文献
8.
Matthew C. Phillips Laura Sarff Josh Banerjee Chase Coffey Paul Holtom Steve Meurer Noah Wald-Dickler Brad Spellberg 《Journal of medical virology》2022,94(1):318-326
When hospitals first encountered coronavirus disease 2019 (COVID-19), there was a dearth of therapeutic options and nearly 1 in 3 patients died from the disease. By the summer of 2020, as deaths from the disease declined nationally, multiple single-center studies began to report declining mortality of patients with COVID-19. To evaluate the effect of COVID-19 on hospital-based mortality, we searched the Vizient Clinical Data Base for outcomes data from approximately 600 participating hospitals, including 130 academic medical centers, from January 2017 through December 2020. More than 32 million hospital admissions were included in the analysis. After an initial spike, mortality from COVID-19 declined in all regions of the country to under 10% by June 2020 and remained constant for the remainder of the year. Despite this, inpatient, all-cause mortality has increased since the beginning of the pandemic, even those without respiratory failure. Inpatient mortality has particularly increased in elderly patients and in those requiring intubation for respiratory failure. Since June 2020, COVID-19 kills one in every 10 patients admitted to the hospital with this diagnosis. The addition of this new disease has raised overall hospital mortality especially those who require intubation for respiratory failure. 相似文献
9.
Lesmana Cosmas Rinaldi Adithya Paramitha Maria Satya Gani Rino A. Lesmana Laurentius A. 《Journal of Medical Ultrasonics》2022,49(3):359-370
Journal of Medical Ultrasonics - Chronic liver disease is still a major problem because disease progression will ultimately lead to liver cirrhosis. Portal hypertension is the hallmark in advanced... 相似文献
10.